HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Protalix BioTherapeutics (AMEX:PLX) and maintained a price target of $10.
November 14, 2023 | 11:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Protalix BioTherapeutics and maintained a $10 price target.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst could lead to increased investor confidence and a potential short-term increase in the stock price of PLX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100